vial of retatrutide Vial of unapproved peptide retatrutide

View the Phase 2 retatrutide trial on PubMed

These include heart palpitations, chest pain, shortness of breath, or loss of consciousness

[1] [2] This trial enrolled adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity the primary cohort was largely without type 2 diabetes and assessed multiple doses of retatrutide against placebo over 24 weeks, with an extension to 48 weeks

In this study we demonstrate how in-depth physiological characterization of a GWAS signal can lead to biological insight and subsequent focused examination of pharmacogenetic studies can provide implications for a currently available treatment

A systematic review suggests that ginseng supplementation may improve fasting blood glucose levels, though the evidence is inconsistent